Chiltern Releases System for Capturing, Managing, and Reporting Clinical Research Data
London, U.K., and Wilmington, N.C.; June 8, 2017 - Chiltern, a global contract research organization, announced the release of its new Medidata Rave® Value Accelerators, a system of tools designed to capture, manage, and report clinical research data. The tools streamline the clinical trial process and help trial sponsors cut the time, cost, and effort of bringing a new device to market.
“Our partnership with Medidata and its industry-leading platform aligns with our strategy providing an exceptional customer experience around best-in-class technologies,” said Mark Penniston, executive vice president, clinical analytics, and general manager at Chiltern. “Currently our Data & Analysis team leads the field in providing the latest platforms and technologies and the Medidata Rave Value Accelerators support our stronghold in the technology space.”
Included are three accelerator tools: the Chiltern EC Reviewer for Medidata Rave®, Chiltern EC Detector for Medidata Rave®, and Chiltern EC Analyzer for Medidata Rave®. They are designed to create flexibility for users, helping them accommodate their workflow environments, and they are scalable from one study to hundreds and from Phase I to global Phase IV studies.
The tools function in any type of study requirement-from simple to complex-out of the box or customized to our customer’s process. Not only can sponsors select which tools are appropriate for their needs but they can be used anytime and anywhere, and by multiple users during the setup and conduct of the trial.
Over the course of the next year there will be more tools available. To learn more about Chiltern’s services and technologies, visit Chiltern.com or request a demo at the Drug Information Association Annual Meeting in Chicago, June 19–21, in booth 1807.
About Chiltern
Chiltern, a global contract research organization, is a leading provider of clinical services and solutions in a variety of therapeutic areas with engagement models for biopharmaceutical and medical device industries. Chiltern’s team of more than 4,300, located across 47 countries, provides comprehensive Clinical Development, Medical & Scientific Affairs, Data & Analysis, Pharmacovigilance and Strategic Regulatory services using a collaborative approach for more efficient clinical trials. Visit Chiltern.com to learn more about how Chiltern is Designed Around You®.
CONTACT:
Lea Studer
SCORR Marketing
308-237-5567
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
